Key Takeaways
- Solid quarter, margin-led beat: Revenue grew 15.2% YoY while PAT jumped 47% YoY, driven by gross margin expansion of 154 bps and operating leverage.
- Trade Generics is the growth engine: The vertical grew 37% YoY in Q2 and 52% in H1, scaling rapidly via a capital-light, channel-based model targeting underserved rural markets.
- Exports are a five-year story: Revenue collapsed 54% YoY as the company deliberately stopped supplying Sri Lanka and Myanmar to avoid payment risk; management urges investors to judge this vertical on a multi-year horizon.
- Injectable CAPEX delayed, not derailed: A vendor switch from Chinese suppliers has pushed mechanical completion to March 2023, with commercial production now expected by mid-Q2 FY24.
- What to watch next quarter: Whether the South Africa product commercializes on schedule in Q4, the pace of Trade Generics geographic expansion outside northern states, and any inorganic deal closure after one target was rejected this quarter.
CDMO: The Base Business
- Steady growth with margin stability: CDMO revenue grew 17% YoY to ₹106.6 crores in Q2, contributing ~80% of consolidated revenue, with growth led by new product launches and new account wins.
- Cost-plus model as a shield: The cost-plus structure and higher Trade Generics gross margins enabled stable profitability despite volatile input costs, though inventory days rose as the company built safety stock for critical raw materials.
- Differentiation through innovation: When market volume growth is low, customers seek new ideas; the company responds by bringing products with DCGI approvals, bio-equivalent studies, and sometimes clinical trial studies, such as the recent Sitagliptin+Metformin SR combination launch.
- Customer diversification underway: Top 10 customer contribution fell to 43% in Q2 from higher levels earlier, a sign management calls healthy for CDMO growth.
- Capacity planning is proactive: Current capacity can support up to ~₹600 crores in revenue; as utilization inches toward 50-55%, the company will begin creating capacity for another unit because CDMO capacity must be built in advance.
Hitesh Windlass: "When the volume growth is not very high, our customers also look for new innovative ideas. And that is where, you know, we are trying to sort of differentiate ourselves and say and bring new products with DCGI approvals with bio equivalent studies and sometimes even clinical trial studies."
Trade Generics: The Growth Bet
- Scaling fast from a small base: Q2 revenue of ₹23.1 crores grew 37% YoY, following >70% growth in Q1, with the vertical now contributing ~17-18% of consolidated revenue.
- A different distribution model: Products are sold through channel substitution, not medical reps; retailers give consumers a 15-20% discount on MRP, and the absence of a large sales force keeps costs low while branding remains consistent with branded generics.
- Rural India is the target: The focus is on villages and kasabas (6.5 lakh+ locations) where ~70% of India resides and the traditional medical rep model fails due to lack of doctors; the portfolio is primary care rather than highly sophisticated molecules.
- Three expansion levers: Geographic expansion from northern states outward, portfolio expansion by adding SKUs while trimming underperformers, and umbrella branding to establish "Windlas Generics" as a trusted alternative for affordable, authentic medicines.
- Injectable SKU added: The company has already added an injectable SKU in Trade Generics to build that business and bring volume in-house once the injectable plant is ready.
Hitesh Windlass: "We are looking at it as a triple A approach. Authentic products, affordable prices, and accessible medicines."
Exports: Deliberate Retreat, Long-Term Ambition
- Revenue collapsed by choice: Q2 exports fell 54% YoY to ₹2.5 crores as the company stopped supplies to Sri Lanka due to a currency and payment crisis, and to Myanmar where customers struggle with foreign exchange constraints; management chose to be conservative rather than risk getting money stuck.
- The US is off the table: Management is not pursuing the US market for the foreseeable future due to significant margin erosion, focusing instead on EU GMP-approved markets (PICS countries), South Africa (SAHPRA-approved), Southeast Asia, Africa, and CIS.
- South Africa is the nearest catalyst: One product has already been approved and should commercialize in Q4; another is closely following, with revenues expected to begin this fiscal year.
- Market authorizations are the bottleneck: Filing to approval takes 1.5-2 years, so the company is exploring inorganic routes to acquire market authorizations rather than building everything organically through dossier preparation.
- Long-term target intact: The goal remains to grow exports to 3x the original size (₹25 crores to ₹75 crores) by end of 2025, but management insists this vertical must be judged on a five-year horizon given the small base and long incubation periods.
Hitesh Windlass: "From an export perspective, you should look at the full year kind of a horizon and not anything sooner because all of these will be sort of needles in the fire until it finally emerges and comes from that."
Injectable CAPEX & Capacity Expansion
- Timeline slipped on vendor change: Mechanical completion is now expected by end of March 2023, followed by a minimum three-month media fill and qualification period; commercial production is now anticipated by end of Q1 or middle of Q2 FY24, a delay from the earlier March 2023 expectation.
- Vendor switch from China: The original Chinese supplier caused significant delays, prompting a switch to a new vendor; machinery has been ordered.
- IPO proceeds nearly deployed: ~₹100 crores of the ₹153.1 crores raised has been utilized (~65%), with the remainder mostly earmarked for injectable CAPEX and expected to be spent before the March 2023 mechanical completion date.
- Commercialization path: The company is in discussions with CDMO partners for various dosage forms; commercialization will begin with own products supplied in the Trade Generics institutional market, while CDMO supply requires partner quality inspections and approvals.
- European CDMO interest emerging: Some customers have approached the company to do CDMO for their European demand, though these are longer-term projects involving batch execution, freight transfers, and regulatory approvals.
Capital Allocation & Inorganic Strategy
- Buyback announced: The board approved a share buyback program up to ₹25 crores with no promoter participation, described as a strategic decision to return surplus funds after assessing medium-term operational cash needs.
- One deal rejected this quarter: The company conducted legal, financial, and quality diligence on one asset but found adverse findings and decided not to pursue it; diligence costs were absorbed in Q2's P&L.
- Actively hunting, no timeline: Management is evaluating several opportunities and wants to play a significant role in market consolidation, maintaining strategic reserves for potential inorganic growth, but no timeline for completion is given.
- API is a strategic tool, not a business: The company is not looking to enter the API business as a standalone vertical; the pilot facility is viewed as a strategic tool for patent-expiry situations rather than backward integration.
- Land acquired: The company acquired land for business purposes in October, though no specific use was detailed.
Hitesh Windlass: "In this quarter, actually, we, in fact, conducted legal, financial and quality diligence on one asset, and we found some adverse things that, we decided not to pursue that. In fact, some of those diligence costs are also included in our this quarter's P&L."
Margins & Financial Health
- Gross margin expansion: Gross margins came in 154 bps higher YoY, with H1 gross margin at ~36%; management expects this to sustain in the 35-37% range, with potential slight upside as higher-margin Trade Generics contributes more to the revenue mix.
- EBITDA margin improved: EBITDA margins expanded ~70 bps YoY to 12.1% in Q2, achieved despite an inflationary and volatile business environment.
- PAT growth outpaced revenue: PAT grew 47% YoY in both Q2 and H1, significantly ahead of the 15.2% and 11.7% top-line growth rates, reflecting operating leverage and margin discipline.
- Inventory build is deliberate: Inventory days increased as the company began maintaining safety stock for critical raw and packing materials, a move that enabled the growth delivered in Q2.
- Input cost volatility easing: Input costs have generally stabilized from Q1 to Q2, though management cautions that predictability may still not be fully restored.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Injectable facility commercial production | Mechanical completion by March 2023, then 3-4 months qualification; production start | End Q1 to mid Q2 FY24 |
| South Africa export revenue | One product approved, another closely following; commercialization expected | Q4 FY23 |
| Five-year growth targets | 2x CDMO, 3x Trade Generics, 4x exports (from base) | By 2025 end |
| Gross margin range | Sustain at 35-37%, potential slight increase as Trade Generics mix grows | Ongoing |
| Capacity expansion trigger | Begin creating next unit when utilization reaches 50-55% | When current capacity (~₹600 Cr) approaches limit |
| Exports long-term target | Grow to ₹75 crores (3x of original ₹25 Cr base) | By 2025 end |
| IPO proceeds deployment | Remaining funds spent on injectable CAPEX | Before March 2023 mechanical completion |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue growth | 15.2% YoY |
| CDMO revenue | ₹106.6 cr, +17% YoY |
| Trade Generics revenue | ₹23.1 cr, +36.8% YoY |
| Exports revenue | ₹2.5 cr, -54.1% YoY |
| CDMO revenue share | ~80% of consolidated revenue |
| Trade Generics revenue share | ~17% of consolidated revenue |
| Gross margin | ~36% (H1 FY23), +154 bps YoY for Q2 |
| EBITDA margin | 12.1%, +67 bps YoY |
| PAT | ₹12.2 cr, +47% YoY |
| Complex generics share | ~80% of product mix |
| Top 10 customer concentration | 43% of revenue, down from 45% in H1 |
| Capacity utilization | 44% |
| Trade Generics product count | ~200 SKUs |
| IPO proceeds utilized | ₹100 cr, 65% of ₹153.1 cr raised |
| Buyback approved | ₹25 cr, no promoter participation |